Previous 10 | Next 10 |
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that results from the CONVERGE IDE trial have been accepted for presentation in the late-breaking abstract sessions at the Heart Rhyt...
Citing COVID-19 disruptions, AtriCure (NASDAQ: ATRC ) is withdrawing its previously issued financial guidance for 2020. More news on: AtriCure, Inc., Healthcare stocks news, , Read more ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the first quarter 2020 and provided updates in response to the COVID-19 pandemic. “Throu...
AtriCure, Inc. (ATRC) Q4 2019 Results Earnings Conference Call February 18, 2020 04:30 PM ET Company Participants Lynn Lewis - Gilmartin Group, Investor Relations Mike Carrel - President and Chief Executive Officer Andy Wade - Chief Financial Officer Conference Call Participan...
Image source: The Motley Fool. AtriCure Inc (NASDAQ: ATRC) Q4 2019 Earnings Call Feb 18, 2020 , 4:30 p.m. ET Operator Continue reading
AtriCure (NASDAQ: ATRC ): Q4 Non-GAAP EPS of -$0.37 beats by $0.03 ; GAAP EPS of -$0.42 in-line. More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
2019 Worldwide revenue of $230.8 million – an increase of 14.5% year over year 2019 U.S. revenue of $185.8 million – an increase of 14.6% year over year 2019 International revenue of $45.0 million – an increase of 13.9% year over year AtriCure, Inc . ( N...
BTIG Research has restarted coverage on the following: More news on: Abbott Laboratories, Abiomed, Inc., AtriCure, Inc., Healthcare stocks news, , Read more ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 9 th Annual Global Healthcare Conference in New York Cit...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2019 financial results on Tuesday, February 18, 2020. AtriCure will host a ...
News, Short Squeeze, Breakout and More Instantly...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 44th...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products A...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2024 financial results on Tuesday, Ju...